Samuel Stevens, Common Sense Oncology Fellow in Cancer Policy at Queen’s University and VMO – Medical Oncologist at NSW Health, shared a post on LinkedIn:
“A must watch discussion by Meredith Regan in the metastatic breast cancer session. No, we can’t declare a ‘new standard of care’ based on exploratory analyses of dubious intermediate endpoints… however there is clearly a need for useful intermediate endpoints as we try and get the balance of speed and certainty right.
Catch up Meredith’s great discussion online to learn about some potential solutions: time to first subsequent treatment (TFST) or time to second subsequent treatment (TSST) are clearer, but these too require rigorous validation on an individual patient level.”
Other articles about breast oncology on OncoDaily.
